BioRxiv

Ring Therapeutics Publishes a Novel Gene Delivery Platform Based on the Commensal Human Anellovirus

Retrieved on: 
Monday, April 1, 2024
Cell, Patient, Mouse, Flagship Pioneering, MD, Tropism, Biology, MBA, Iris (anatomy), Publication, Therapy, RPE, Immune system, Immune privilege, BioRxiv, Vaccine

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize programmable medicines with its commensal virome platform, today announced a pre-print publication in bioRxiv featuring the first gene delivery vector system based on a human commensal virus, the anellovirus. These data support the immense promise of Ring’s AnellogyTM platform, harnessing the unique biology of commensal anelloviruses to engineer the next generation of durable and potentially redosable programmable viral vectors.

Key Points: 
  • – Publication describes the first gene delivery vector system based on a human commensal virus, the anellovirus –
    CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize programmable medicines with its commensal virome platform, today announced a pre-print publication in bioRxiv featuring the first gene delivery vector system based on a human commensal virus, the anellovirus.
  • These data support the immense promise of Ring’s AnellogyTM platform, harnessing the unique biology of commensal anelloviruses to engineer the next generation of durable and potentially redosable programmable viral vectors.
  • “We set out to develop an entirely new vector system based on human commensal viruses to address the many hurdles facing current genetic medicine delivery – and we’ve achieved that goal at remarkable speed,” said Tuyen Ong, MD, MBA, Chief Executive Officer of Ring and CEO-Partner at Flagship Pioneering.
  • This technology could enable the Anellogy platform to take advantage of the remarkable diversity of anelloviruses.

Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers

Retrieved on: 
Tuesday, April 9, 2024
AXL, Infection, Drug discovery, COVID-19, RNA-dependent RNA polymerase, FACP, FIDSA, RNA, Research, Publishing, AI, UC San Diego Health, Deep learning, GALILEO, Preprint, Orthornavirae, Therapy, Pandemic, BioRxiv, MAS, BRD4

LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.

Key Points: 
  • LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.
  • Using bioinformatics and deep learning, they also found MDL-001 to be a promising orally bioavailable broad-spectrum antiviral that blocks the RdRp Thumb-1 site.
  • In the second preprint, "ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery" , Model Medicines details their foundational GALILEO AI platform and its core ChemPrint deep learning model for molecular property prediction.
  • By employing adaptive molecular embeddings and rigorous model training and validation methods, ChemPrint substantially outperformed conventional AI approaches.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Retrieved on: 
Wednesday, March 13, 2024
Neurology, Serum, EAE, Multiple sclerosis, ALS, Disease, Patient, Biomarker, Masitinib, Research, Mouse, Science, University, MD, Euronext, Alzheimer's disease, Cytokine, AN, BioRxiv, FDA, NFL, Nerve, FIRST, AFL, NDD, Guideline, Pharmaceutical industry

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.

Key Points: 
  • Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.
  • The neuroprotective action of masitinib was studied in an animal model of experimental autoimmune encephalitis (EAE).
  • Results showed that masitinib can significantly lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical symptoms.
  • Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease.

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

Retrieved on: 
Tuesday, April 2, 2024
TUSC2, Toxicity, LLC2, Gene, Growth, NSCLC, Diabetes, Risk, Patient, Lung, Neoplasm, Glioma, Mouse, Manuscript, Cancer, Pembrolizumab, NPRL2, Lung cancer, Stomach, BioRxiv, Hepatocellular carcinoma, NK, Natural killer T cell

AUSTIN, Texas, April 2, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing the Company's non-viral Oncoprex® Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (NSCLC) in a humanized mouse model.

Key Points: 
  • Genprex's Oncoprex® Delivery System is a novel non-viral approach that utilizes lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor genes deleted during the course of cancer development.
  • Genprex believes this system allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer.
  • "These positive preclinical data are very encouraging and support NPRL2 gene therapy as a potential treatment for a sub-group of NSCLC in which patients traditionally are resistant to existing therapies," said Rodney Varner, President, Chairman and Chief Executive Officer at Genprex.
  • In conclusion, researchers reported that NPRL2 gene therapy induces anti-tumor activity through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation.

Basecamp Research Launches BaseFold: A Breakthrough in 3D Protein Structure Prediction of Large, Complex Protein Structures

Retrieved on: 
Tuesday, March 12, 2024
Research, Genomics, Health, Algorithm, Database, Biotechnology, Drug discovery, Intelligence, AlphaFold, 3D, Acquisition, AI, Protein, Deep learning, Biodiversity, Drug development, Therapy, Data, BioRxiv, NVIDIA, Work, Medical device

LONDON, March 12, 2024 /PRNewswire/ -- Basecamp Research, a world leader in artificial intelligence (AI)-based design of proteins and other biological systems, today announced the launch of BaseFold, its new deep learning model that predicts 3D structures of large, complex proteins more accurately than other AI-powered tools, including the industry gold standard, AlphaFold2. These data were recently published in bioRxiv.

Key Points: 
  • BaseFold was created by augmenting the AlphaFold2 model, which predicts the 3D structure of a protein based on its amino acid sequence, with BaseGraph.
  • Furthermore, Basecamp Research will be working with NVIDIA to optimise and productionise BaseFold for NVIDIA BioNeMo , a generative AI platform for drug discovery.
  • The scientific benchmark for determining protein structure is still via slow and time-consuming experimental methods such as X-ray crystallography.
  • A wide array of structure prediction models have since followed AlphaFold2, most notably CollabFold, ESMFold, OpenFold and RoseTTAFold.

Basecamp Research Launches BaseFold: A Breakthrough in 3D Protein Structure Prediction of Large, Complex Protein Structures

Retrieved on: 
Tuesday, March 12, 2024
Research, Genomics, Health, Algorithm, Database, Biotechnology, Drug discovery, Intelligence, AlphaFold, 3D, Acquisition, AI, Protein, Deep learning, Biodiversity, Drug development, Therapy, Data, BioRxiv, NVIDIA, Work, Medical device

LONDON, March 12, 2024 /PRNewswire/ -- Basecamp Research, a world leader in artificial intelligence (AI)-based design of proteins and other biological systems, today announced the launch of BaseFold, its new deep learning model that predicts 3D structures of large, complex proteins more accurately than other AI-powered tools, including the industry gold standard, AlphaFold2. These data were recently published in bioRxiv.

Key Points: 
  • BaseFold was created by augmenting the AlphaFold2 model, which predicts the 3D structure of a protein based on its amino acid sequence, with BaseGraph.
  • Furthermore, Basecamp Research will be working with NVIDIA to optimise and productionise BaseFold for NVIDIA BioNeMo , a generative AI platform for drug discovery.
  • The scientific benchmark for determining protein structure is still via slow and time-consuming experimental methods such as X-ray crystallography.
  • A wide array of structure prediction models have since followed AlphaFold2, most notably CollabFold, ESMFold, OpenFold and RoseTTAFold.

Animal Biosciences Announces New Canine Clinical Research Evaluating Reversal of Age-Related Signs in Dogs

Retrieved on: 
Tuesday, March 5, 2024
Veterinary, Research, Pets, Clinical Trials, Biotechnology, Health, Consumer, General Health, Science, Pet, Doctor of Philosophy, Dementia, Quality of life, Ageing, Animal, Dog, Neurology, NCSU, Gene expression, Happiness, Cognition, Clinical trial, Frailty, Harvard Medical School, Genetics, BioRxiv, Human, Pharmaceutical industry

Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.

Key Points: 
  • Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.
  • After five years of development and testing in dogs, leveraging discoveries made at Harvard Medical School, the study shows the first clinical evidence that it is possible to reverse age-related decline in dogs.
  • "The outcomes of the clinical trial, especially the enhancements in cognition, are encouraging and represent a unique achievement,” Dr. Olby noted.
  • In senior dogs, as in humans, this age-related decline can manifest as cognitive decline, increased frailty and lower engagement.

Fauna Bio Scientist Announces New Research into Muscle Metabolism in Hibernating Mammals

Retrieved on: 
Wednesday, February 7, 2024
Paper, BioRxiv, Hibernation, Research, Physiology, Mammal, Drug discovery, ATP, Genomics, Thermogenesis, Metabolism, Preprint, Doctor of Philosophy, Health, Hunting

The study, titled " Remodelling of Skeletal Muscle Myosin Metabolic States in Hibernating Mammals ," sheds light on the metabolic adaptations employed by hibernating mammals to survive the harsh winter months.

Key Points: 
  • The study, titled " Remodelling of Skeletal Muscle Myosin Metabolic States in Hibernating Mammals ," sheds light on the metabolic adaptations employed by hibernating mammals to survive the harsh winter months.
  • In the study, muscle fibers from various hibernating mammals were isolated and subjected to comprehensive analyses, including loaded Mant-ATP chase experiments and proteomics analyses.
  • In particular, the study found that resting myosin is altered in hibernating mammals, contributing to significant changes to the ATP consumption of skeletal muscle.
  • "This study provides unprecedented insights into the metabolic dynamics of hibernating mammals' skeletal muscle," said Ashley Zehnder, CEO & Co-Founder, Fauna Bio.

Vizgen Kicks Off AGBT with Enhanced MERFISH Chemistry Updates and 2024 Product Roadmap Highlights

Retrieved on: 
Monday, February 5, 2024
Neurology, Health, Genetics, Science, Research, Partnership, RNA, Sunset Terrace/Montclair, Houston, Data management, Glass, Mass meeting, Gene, Brain, Gene expression profiling, BioRxiv, Biology, Software

Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap.

Key Points: 
  • Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap.
  • In addition to the announcement of these product developments, Vizgen will be presenting three posters at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting, in Orlando, Florida, this week.
  • The enhanced MERFISH chemistry will extend the best-in-class sensitivity of MERFISH to degraded RNA samples, including archival FFPE samples, enabling translational research.
  • Data demonstrating this superior detection capacity is expected to be released in the coming months, with plans to make the enhanced MERFISH chemistry available to users in the summer of 2024.